News & Investors

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Cara Therapeutics Initiates Phase II Trial of Novel Analgesic In Acute Post-Operative Pain
Peripherally-Acting Kappa Opioid Agonist, CR845, to Be Studied in Both Pre- and Post-Operatove Drug Regimens
View HTML
Toggle Summary Cara Banks $15M for Pursuit of Nonaddictive Pain Drug, by Donna Young (BioWorld Today)
Cara Banks $15M for Pursuit of Nonaddictive Pain Drug, by Donna Young (BioWorld Today) The $15 million Series D financing Cara Therapeutics Inc. closed this week will go a long way toward advancing the development of its peripherally restricted kappa opioid agonist CR845, said CEO Derek Chalmers...
View HTML
Toggle Summary Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845
CR845, a novel, peripherally restricted kappa opioid agonist, is currently in Phase 2 development for treatment of post-operative pain
View HTML
Toggle Summary Cara's No-Brainer Opioid Solution
Cara's No-Brainer Opioid Solution San Carlos, CA, Feb 22, 2010 /The Bernstein Report on BioBusiness/ — Cara Therapeutics, Inc. believes its CR845 kappa opioid agonist will fare better than others because the peptide is too large to cross the blood-brain barrier, meaning it should avoid the side
View HTML
Toggle Summary Cara Therapeutics Reports Positive Phase II Data for Novel Peripheral Analgesic In Acute Post-Operative Pain
Cara Therapeutics Reports Positive Phase II Data for Novel Peripheral Analgesic In Acute Post-Operative Pain Shelton, CT, Feb 8, 2010 /PRNewswire-FirstCall/ — Cara Therapeutics, Inc. today announced positive data in a Phase II proof-of-concept clinical trial of its peripherally-restricted kappa
View HTML
Toggle Summary Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic In Acute Post-Operative Pain
Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic In Acute Post-Operative Pain Shelton, CT, Jan 12, 2009 /PRNewswire-FirstCall/ — Cara Therapeutics, Inc. today announced that it is initiating a Phase II clinical trial of its long-acting peripheral kappa opioid agonist,
View HTML
Toggle Summary Pharmacological Profile of a Novel Series of CB2-Selective Agonists with Efficacy in Visceral, Inflammatory, and Neuropathic Pain" View HTML
Toggle Summary "Preclinical Profile of CR845" View HTML
Toggle Summary Development of the Novel, Peripherally-Selective Kappa Opiod Agonist CR665 for the Treatment of Acute Pain View HTML
Toggle Summary Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845 Cara Therapeutics, Inc. today announced completion of a Phase I clinical trial for its second-generation, peripherally acting kappa opioid agonist, CR845, under development for the treatment of
View HTML